HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.

Abstract
Human plasma butyrylcholinesterase (BChE) contributes to cocaine metabolism and has been considered for use in treating cocaine addiction and cocaine overdose. TV-1380 is a recombinant protein composed of the mature form of human serum albumin fused at its amino terminus to the carboxy-terminus of a truncated and mutated BChE. In preclinical studies, TV-1380 has been shown to rapidly eliminate cocaine in the plasma thus forestalling entry of cocaine into the brain and heart. Two randomized, blinded phase I studies were conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of TV-1380, following single and multiple administration in healthy subjects. TV-1380 was found to be safe and well tolerated with a long half-life (43-77 hours) and showed a dose-proportional increase in systemic exposure. Consistent with preclinical results, the ex vivo cocaine hydrolysis, TV-1380 activity clearly increased upon treatment in a dose-dependent manner. In addition, there was a direct relationship between ex vivo cocaine hydrolysis (kel ) and TV-1380 serum concentrations. There was no evidence that TV-1380 affected heart rate, the uncorrected QT interval, or the heart-rate-corrected QTcF interval. TV-1380, therefore, offers a safe once-weekly therapy to increase cocaine hydrolysis.
AuthorsOrit Cohen-Barak, Jacqueline Wildeman, Jeroen van de Wetering, Judith Hettinga, Petra Schuilenga-Hut, Aviva Gross, Shane Clark, Merav Bassan, Yossi Gilgun-Sherki, Boaz Mendzelevski, Ofer Spiegelstein
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 55 Issue 5 Pg. 573-83 (May 2015) ISSN: 1552-4604 [Electronic] England
PMID25524052 (Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2015 The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology.
Chemical References
  • Albumins
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • TV-1380
  • Butyrylcholinesterase
  • Cocaine
Topics
  • Adult
  • Albumins (adverse effects, pharmacokinetics, pharmacology)
  • Area Under Curve
  • Butyrylcholinesterase (adverse effects, pharmacokinetics, pharmacology)
  • Cocaine (metabolism)
  • Cocaine-Related Disorders (drug therapy)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Electrocardiography
  • Female
  • Half-Life
  • Humans
  • Injections, Intramuscular
  • Male
  • Maximum Tolerated Dose
  • Metabolic Clearance Rate
  • Recombinant Fusion Proteins (adverse effects, pharmacokinetics, pharmacology)
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: